ADAR1 Capital Management »

Nextcure shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Nextcure (NXTC) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Nextcure

Tip: Access up to 7 years of quarterly data

All positions including Nextcure held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Nextcure by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $69k 60k 1.14

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Royalty Pharma Shs Class A (RPRX)
Keros Therapeutics (KROS)
Roivant Sciences SHS (ROIV)
Cytokinetics Com New (CYTK)
Arbutus Biopharma (ABUS)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New (MACK)
Cerevel Therapeutics Hldng I (CERE)
Mirati Therapeutics
Merck & Co (MRK)
Ascendis Pharma A/s Sponsored Adr (ASND)
Immunovant (IMVT)
Viking Therapeutics (VKTX)
Protagonist Therapeutics (PTGX)

View all positions for ADAR1 Capital Management

Top funds holding Nextcure

OrbiMed Advisors
Millennium Management
Vanguard Group
Cable Car Capital
Long Focus Capital Management
Tang Capital Management
Assenagon Asset Management
Citadel Advisors
Acuitas Investments
Federated Investors
BML Capital Management
Dimensional Fund Advisors
Barclays
ADAR1 Capital Management
Marquette Asset Management

View all funds holding Nextcure